Toggle light / dark theme

Stage is set to develop clinically relevant, senescence-based biomarkers of aging

Researchers at the Buck Institute have extensively profiled the various inflammatory signals given off by senescent human cells and have generated a curated database available for use in the field.


Senescent cells, which stop dividing under stress, are long- recognized drivers of multiple diseases of aging. Mouse studies have shown that targeted removal of these cells and the inflammatory factors they secrete, known as the senescence-associated secretory phenotype (SASP), has beneficial results on multiple organ systems and functions. Success in the laboratory has given rise to companies and research projects aimed at developing either senolytics, drugs that clear senescent cells, or senomorphics, drugs that suppress the SASP. But drug development and clinical utilization require simple, reliable biomarkers to assess the abundance of senescent cells in human tissues. Publishing in PLOS Biology, researchers at the Buck Institute have extensively profiled the SASP of human cells and have generated a curated database available for use in the field.

“The stage is now set for the development of clinically-relevant biomarkers of aging,” said Judith Campisi, Ph.D., Buck professor and one of the senior authors on the paper. “This will speed efforts to get safe and effective drugs into the clinic and, in the long term, could enable physicians to give patients a clear read-out of how well, or poorly, their various tissues and organs are aging.”

The study, led by postdoc Nathan Basisty, Ph.D., expanded the number of proteins known to be secreted by human by about 10-fold, to over 1000. Researchers show that a ‘core’ set of senescence factors, which were secreted by all types of senescent cells studied, are significantly increased in human plasma as we age, and may be the basis for developing “whole body” biomarkers of aging, and biomarkers to assess the efficacy of senolytics and senomorphics in human trials. Using advanced proteomic analysis, researchers also propose signatures that identify specific subsets of senescent cells.

Tesla just filed a new battery patent. Is this the promised million-mile battery?

How long should an EV battery last? Elon Musk seems to think that a million miles is just about right — last April he announced that Tesla had a “1 million-mile battery pack” in the pipeline. That’s an ambitious goal, to say the least — do we really need a battery that lasts three to four times as long as a typical car? We will.

Source: Charged

As a recent article posted on Forbes points out, while today’s typical Li-ion battery packs are more than adequate for individual EV owners, applications such as taxi services and long-distance trucking will require batteries optimized for longevity (according to writer Ariel Cohen, the average trucker logs some 100,000 to 150,000 miles per year). Thus, long-life batteries are likely to be critical to the success of the Tesla Network (a proposed fleet of robo-taxis) and the Tesla Semi.

Discover Longevity and Anti-Aging Science Past, Present and Future

Ira Pastor, ideaXme exponential health ambassador, interviews Dr. Magomed Khaidakov, Assistant Research Professor, Department of Internal Medicine, University of Arkansas for the Medical Sciences. https://www.amazon.com/Pessimistic-Guide-Anti-aging-Research…atfound-20

Ira Pastor Comments

Today we are going to be talking about mitochondria, among many other longevity and anti-aging themed topics.

We’re also going to talk a little bit about the role of pessimism and realism when it comes to the human translation of certain technologies, and why it is important to limit “messianic thinking” as much as possible.

Mitochondria

The mitochondria are double-membrane-bound organelles found in most eukaryotic organisms and are responsible for generating most of the cell’s supply of adenosine triphosphate (ATP), used as a source of chemical energy. Thus mitochondria is termed the “powerhouse of the cell.”

3D Systems and CollPlant Biotechnologies Join Forces to Accelerate Breakthroughs in Regenerative Medicine

ROCK HILL, South Carolina and REHOVOT, Israel , January 13, 2020 – Today, 3D Systems (NYSE: DDD) and CollPlant Biotechnologies (NASDAQ: CLGN), announced signing a joint development agreement intended to play a pivotal role in advancing and accelerating breakthroughs in the biomedical industry. The collaboration brings together two industry pioneers—3D Systems, renowned for its 3D printing technologies and healthcare expertise; and CollPlant, the developer of proprietary recombinant human collagen (rhCollagen) BioInk technology currently used for 3D bioprinting of tissues and organs. The two companies plan to jointly develop tissue and scaffold bioprinting processes for third party collaborators.

Can George Church Reverse Aging by 2030?

If you look up ‘scientific overachiever’ in the dictionary, you’re likely to find a two-word definition: George Church.

The American geneticist, molecular engineer, and chemist splits his time between roles as Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT. He’s also a member of the National Academy of Sciences, acts as an advisor to a plethora of cutting edge companies, and heads up synthetic biology at the Wyss Institute for Biologically Inspired Engineering, of which he’s a founding member.

Oh, and George is author to hundreds of published papers, 60 patents and a popular science book (also, theoretically, George Church may live in an alternate reality where there are more than 24 hours in a day).

/* */